Annual Results 2021
"Together we made incredible progress during 2021, setting the stage for what could be a transformative 2022. We will do our utmost to deliver continued shareholder and future patient value," said Jeppe Øvlesen, CEO.Fourth Quarter (October – December) · Net sales during the period amounted to 0 (0) TSEK. · Loss before tax amounted to -26,207 (-9,786) TSEK. · Earnings per share amounted to -1.01 (-0.35) SEK. · Cash flow from operating activities amounted to -20,257 (-11,137) TSEK. · Cash flow from financing activities amounted to -77 (0) TSEK. Full Year (January –